• Company
• Nexviazyme, 1st biobetter to receive preferential pricing
• by Eo, Yun-Ho Aug 21, 2023 05:37am

• Product
• 9 of 10 pediatric patients are prescribed off-label drugs
• by Kang, Shin-Kook Aug 18, 2023 05:20am

• Company
• Hugel HA filler Revolax, obtained product approval
• by Nho, Byung Chul Aug 18, 2023 05:20am

• Company
• HK Inno.N will comarket Roche’s single-dose Xofluza in KOR
• by Kim, Jin-Gu Aug 18, 2023 05:20am

• Policy
• Lower drug dose options trending in chronic diseases
• by Lee, Tak-Sun Aug 18, 2023 05:20am

• Company
• Vabysmo pays attention to entry into reimbursement
• by Eo, Yun-Ho Aug 18, 2023 05:20am

• Company
• Bavencio’s reimb may change the Rx paradigm in KOR
• by Hwang, byoung-woo Aug 17, 2023 05:29am

• Policy
• Will Opdivo soon be reimb as first-line gastric cancer Tx?
• by Lee, Tak-Sun Aug 17, 2023 05:29am

• Opinion
• [Reporter's view] There should be no recurrence of the Champ
• by Lee, Hye-Kyung Aug 17, 2023 05:29am

• Company
• Retevmo fails reimb at the last stage in KOR
• by Eo, Yun-Ho Aug 17, 2023 05:29am